Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis
- PMID: 35254511
- DOI: 10.1007/s00417-022-05602-z
Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis
Abstract
Purpose: Management of NK can be difficult, involving a range of treatments with variable efficacy. We conducted a systematic review and meta-analysis to evaluate the efficacy of medical and surgical treatments for neurotrophic keratitis (NK).
Method: PubMed, Cochrane Library, Embase, ClinicalTrial.gov, and ScienceDirect were searched for studies assessing efficacy of NK treatments. We computed random-effect meta-analyses on corneal healing, time to complete healing, and visual acuity changes between baselines and after treatment, stratified on treatment classes. We followed the PRISMA guidelines (registration number CRD42021225721).
Results: We included 20 studies: 571 patients and 5 treatment classes (2 surgical and 3 non-surgical). The percentage of patients with complete corneal healing did not differ between specific treatments (nerve growth factor eyedrops (NGF), 75%, 95CI 46 to 104%; autologous serum (AS), 92%, 86 to 98%; neurotization, 99%, 95 to 103%; amniotic membrane transplantation (AMT), 86%, 78 to 94%). All specific treatments had better percentage of complete healing (p < 0.001) than non-specific treatment groups, i.e., mainly lubricants (23%, 14 to 32). Time to complete healing was 24.2 days (5.4 to 43.1) with NGF, 27.6 days (15.2 to 40.0) with AS, 117 days (28.8 to 205.2) with neurotization, and 16.4 days (11.1 to 21.7) with AMT. Only NGF and AMT improved visual acuity. Efficacy outcomes were not affected by sociodemographic (age, sex) nor severity of disease (Mackie stages).
Conclusion: We confirmed the efficacy of specific treatments in NK. Further comparative trials are needed to investigate the medical and economic benefits of innovative therapies.
Keywords: Blood products; Corneal ulcer; Grafts; Medication; Nerve; Surgery.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Topical treatment with nerve growth factor for neurotrophic keratitis.Ophthalmology. 2000 Jul;107(7):1347-51; discussion 1351-2. doi: 10.1016/s0161-6420(00)00163-9. Ophthalmology. 2000. PMID: 10889110 Clinical Trial.
-
Neurotrophic keratopathy: current challenges and future prospects.Ann Med. 2022 Dec;54(1):666-673. doi: 10.1080/07853890.2022.2045035. Ann Med. 2022. PMID: 35243932 Free PMC article. Review.
-
Cenegermin: A Review in Neurotrophic Keratitis.Drugs. 2020 Apr;80(5):489-494. doi: 10.1007/s40265-020-01289-w. Drugs. 2020. PMID: 32185680 Review.
-
Clinical and instrumental assessment of the corneal healing in moderate and severe neurotrophic keratopathy treated with rh-NGF (Cenegermin).Eur J Ophthalmol. 2022 Nov;32(6):3402-3410. doi: 10.1177/11206721221097584. Epub 2022 Apr 27. Eur J Ophthalmol. 2022. PMID: 35473440
-
Efficacy and Safety of Nerve Growth Factor in Treating Neurotrophic Keratitis Patients: A Meta-Analysis.Br J Hosp Med (Lond). 2024 Aug 30;85(8):1-17. doi: 10.12968/hmed.2024.0369. Epub 2024 Aug 30. Br J Hosp Med (Lond). 2024. PMID: 39212572
Cited by
-
Topical insulin in neurotrophic keratopathy after diabetic vitrectomy.Sci Rep. 2024 May 14;14(1):10986. doi: 10.1038/s41598-024-60699-y. Sci Rep. 2024. PMID: 38744994 Free PMC article.
-
The Role of Nerve Growth Factor on the Ocular Surface: A Review of the Current Experimental Research and Clinical Practices.Int J Mol Sci. 2025 Jun 23;26(13):6012. doi: 10.3390/ijms26136012. Int J Mol Sci. 2025. PMID: 40649793 Free PMC article. Review.
-
New Promising Therapeutic Approach for Refractory Corneal Epithelial Defects.Cureus. 2023 May 22;15(5):e39324. doi: 10.7759/cureus.39324. eCollection 2023 May. Cureus. 2023. PMID: 37351246 Free PMC article.
-
The Therapeutic Potential of Insulin Eye Drops in Neurotrophic Keratopathy: A Comprehensive Review.Biomedicines. 2025 Jul 7;13(7):1657. doi: 10.3390/biomedicines13071657. Biomedicines. 2025. PMID: 40722729 Free PMC article. Review.
-
Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO).Ophthalmol Ther. 2024 Feb;13(2):553-570. doi: 10.1007/s40123-023-00866-y. Epub 2024 Jan 4. Ophthalmol Ther. 2024. PMID: 38175466 Free PMC article.
References
-
- Saad S, Abdelmassih Y, Saad R et al (2019) Neurotrophic keratitis: frequency, etiologies, clinical management and outcomes. Ocul Surf S1542–0124(19):30400–30408. https://doi.org/10.1016/j.jtos.2019.11.008 - DOI
-
- S Bonini P Rama D Olzi A Lambiase 2003Neurotrophic keratitis Eye Lond Engl 17 989 995 https://doi.org/10.1038/sj.eye.6700616
-
- Dua HS, Said DG, Messmer EM et al (2018) Neurotrophic keratopathy. Prog Retin Eye Res 66:107–131. https://doi.org/10.1016/j.preteyeres.2018.04.003 - DOI - PubMed
-
- L You FE Kruse HE Volcker 2000 Neurotrophic factors in the human cornea 41 11
-
- Müller LJ, Marfurt CF, Kruse F, Tervo TMT (2003) Corneal nerves: structure, contents and function. Exp Eye Res 76:521–542. https://doi.org/10.1016/s0014-4835(03)00050-2 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials